LGL Partners’s SAB Biotherapeutics SABS Stock Holding History

LGL Partners’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,300	Closed	-$14.5K	–	108
2023 Q3	$14.5K	Hold	2,300	–	–	﹤0.01%	93
2023 Q2	$19.1K	Hold	2,300	–	–	﹤0.01%	99
2023 Q1	$10.1K	Hold	2,300	–	–	﹤0.01%	98
2022 Q4	$13.6K	Hold	2,300	–	–	﹤0.01%	93
2022 Q3	$16K	Hold	2,300	–	–	﹤0.01%	155
2022 Q2	$33K	Buy	+2,300	New	+$48.3K	0.01%	99

Other funds holding SABS

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FPB

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LGL Partners's SABS Position: Q4 2023 in Review

LGL Partners sold out of SAB Biotherapeutics (SABS) in Q4 2023, closing a stake of 2,300 shares — an estimated $14.5K sold.

LGL Partners first reported a position in SABS in Q2 2022 and held it in 6 quarters. The position peaked at $33K in Q2 2022. 42 funds tracked by Wall St. Rank hold SABS as of Q4 2023.

LGL Partners reported no remaining SAB Biotherapeutics position as of Q4 2023 after selling out during the quarter.
LGL Partners sold 2,300 SAB Biotherapeutics shares in Q4 2023, an estimated $14.5K.
LGL Partners first reported a position in SAB Biotherapeutics in Q2 2022 and held it in 6 quarters.
LGL Partners's SAB Biotherapeutics position peaked at $33K in Q2 2022.
42 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2023.

Based on LGL Partners's 13F filing for Q4 2023, filed 5 Feb 2024.